At FimmCyte, we are redefining the treatment of endometriosis and other chronic fibro-inflammatory diseases with targeted immunotherapy solutions. Our platform leverages the discovery of a specific protein overexpressed in diseased cells, enabling precise elimination of fibrotic tissue while preserving healthy areas.

The FMC2 antibody is a breakthrough therapy designed to recognize a well-established marker of fibrosis. Using a proprietary binding domain, it recruits immune cells to safely and effectively eliminate diseased tissue. With proven antifibrotic effects, FMC2 addresses critical unmet needs in endometriosis and shows promise for treating other fibrotic conditions.

FimmCyte’s innovative technology positions us as a chronic disease transformer, offering targeted therapies that improve outcomes and transform lives worldwide.

Innovation at Our Core: FimmCyte leads the charge in targeted solutions for women’s health and beyond, with a cutting-edge immunotherapy platform that eliminates diseased tissue without harming healthy cells. This revolutionary approach marks a paradigm shift in treating endometriosis and other fibro-inflammatory diseases.

Our vision extends beyond innovation—we are pioneering first-in-class, disease-modifying treatments to meet the critical needs of a large and underserved market. FimmCyte’s solutions not only tackle chronic conditions but also unlock significant market potential, positioning us as a leader in the biotech landscape.

At FimmCyte, patients are at the heart of everything we do. Our innovative therapies are designed to go beyond symptom management, tackling endometriosis and other chronic conditions at their core. By focusing on disease-modifying treatments, we aim to offer patients new hope, lasting relief, and a significantly improved quality of life.

Our commitment to empowering patients drives us to develop targeted solutions that address the root causes of chronic fibro-inflammatory diseases, providing transformative care for millions worldwide.